产品说明书
Hydroxychloroquine
 |
同义名 : | 羟基氯喹 |
| CAS号 : | 118-42-3 | |
| 货号 : | A862774 | |
| 分子式 : | C18H26ClN3O | |
| 纯度 : | 98% | |
| 分子量 : | 335.872 | |
| MDL号 : | MFCD00242707 | |
| 存储条件： |
粉末 Keep in dark place,Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(312.62 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 1.5 mg/mL(4.47 mM)，配合低频超声，并水浴加热至45℃助溶 1M HCl: 100 mg/mL(297.73 mM)，调节pH至2 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH. HCQ may reduce the risk of flares, allow the reduction of the dosage of steroids, reduce organ damage, and prevent the thrombotic effects of anti-phospholipid antibodies[1].Hydroxychloroquine and its predecessor chloroquine are medications commonly used in the treatment of systemic lupus erythematosus, rheumatoid arthritis, and other connective tissue disorders. Hydroxychloroquine interferes with malarial metabolites, confers immunomodulatory effects, and also affects lysosomal function. Retinal toxicity, neuromyopathy, and cardiac disease are recognized adverse effects of hydroxychloroquine[2]. Moreover, the impact of HCQ on cytokine production and suppression of antigen presentation may have immunologic consequences that hamper innate and adaptive antiviral immune responses for patients with COVID-19[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.98mL 0.60mL 0.30mL |
14.89mL 2.98mL 1.49mL |
29.77mL 5.95mL 2.98mL |
| 参考文献 |
|---|